

Efficacy and Safety of Nevirapine Extended-Release On Immediate-Release Twice-Daily in Treatment-Naive HI

Antiviral Therapy

16, 759-769

DOI: [10.3851/imp1803](https://doi.org/10.3851/imp1803)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?. Patient Preference and Adherence, 2011, 5, 645.	1.8	7
2	Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients. Aids, 2011, 25, 2249-2258.	2.2	57
3	Industry Update: The latest developments in therapeutic delivery. Therapeutic Delivery, 2011, 2, 1527-1533.	2.2	0
4	Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1: A Multicenter, Open-Label Study. Clinical Therapeutics, 2011, 33, 1308-1320.	2.5	10
5	Guidelines for the use of extended-release nevirapine in HIV-infected patients. Expert Opinion on Pharmacotherapy, 2011, 12, 2713-2718.	1.8	4
6	A Review of the Virological Efficacy of the 4 World Health Organizationâ€œRecommended Tenofovir-Containing Regimens for Initial HIV Therapy. Clinical Infectious Diseases, 2012, 54, 862-875.	5.8	61
7	Once-Daily Nevirapine XR. Journal of the International Association of Providers of AIDS Care, 2012, 11, 369-373.	1.2	2
8	Treatment Outcomes of Recommended First-Line Antiretroviral Regimens in Resource-Limited Clinics. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 314-320.	2.1	27
9	Treatment of HIV infection with once-daily regimens. Expert Opinion on Pharmacotherapy, 2012, 13, 2301-2317.	1.8	27
12	Nevirapine extended-release for the treatment of HIV-1 infection. Expert Review of Anti-Infective Therapy, 2012, 10, 21-30.	4.4	4
13	Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment. HIV/AIDS - Research and Palliative Care, 2012, 4, 181.	0.8	0
14	Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations. HIV/AIDS - Research and Palliative Care, 2012, 4, 169.	0.8	8
15	Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200â€œmg twice daily to nevirapine extended release 400â€œmg once daily (TRANxITION). HIV Medicine, 2012, 13, n/a-n/a.	2.2	16
16	The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS). Advances in Pharmacology, 2013, 67, 317-358.	2.0	63
19	Impact of baseline HIVâ€œ1 RNA levels on initial highly active antiretroviral therapy outcome: a metaâ€œanalysis of 12,370 patients in 21 clinical trials*. HIV Medicine, 2013, 14, 284-292.	2.2	25
20	Considerations on the New Nevirapine. Journal of the International Association of Providers of AIDS Care, 2013, 12, 154-156.	1.5	2
21	Advances in antiretroviral therapy. Current Opinion in HIV and AIDS, 2013, 8, 1.	3.8	32
22	Reformulation of existing antiretroviral drugs. Current Opinion in HIV and AIDS, 2013, 8, 550-555.	3.8	4

#	ARTICLE	IF	CITATIONS
23	French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults. <i>Journal of the International AIDS Society</i> , 2014, 17, 19034.	3.0	41
24	Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy. <i>HIV Medicine</i> , 2014, 15, 124-128.	2.2	4
25	Steady-state Pharmacokinetics of Nevirapine Extended-release Tablets in HIV-1-infected Children and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e173-e179.	2.0	5
26	Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials. <i>AIDS Research and Treatment</i> , 2014, 2014, 1-7.	0.7	7
27	Post-Marketing Experience with Nevirapine Extended Release (XR) Tablets: Effectiveness and Tolerability in a Population-Based Cohort in British Columbia, Canada. <i>Antiviral Therapy</i> , 2015, 20, 721-730.	1.0	4
28	Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. <i>HIV Medicine</i> , 2015, 16, 628-634.	2.2	14
29	Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0140574.	2.5	2
30	Nevirapine Extended-Release Formulation Tablets in HIV-1-Infected Children—Long-term Follow-up: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 476-479.	5.8	2
31	Pharmacokinetics of Injectable, Long-Acting Nevirapine for HIV Prophylaxis in Breastfeeding Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 59-66.	3.2	22
32	When can HIV clinical trials detect treatment effects on drug resistance?. <i>International Journal of STD and AIDS</i> , 2015, 26, 268-278.	1.1	1
33	Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 801-808.	2.4	15
34	Improving bioavailability and biodistribution of anti-HIV chemotherapy. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 75, 40-53.	4.0	13
35	Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 156-165.	0.5	12
36	HIV research trials versus standard clinics for antiretroviral-naïve patients: the outcomes differ but do the patients?. <i>International Journal of STD and AIDS</i> , 2016, 27, 537-542.	1.1	2
37	Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2016, 34, 361-371.	0.5	10
38	Stratégie thérapeutique dans l'infection à virus de l'immunodéficience humaine. <i>Actualités Pharmaceutiques</i> , 2017, 56, 17-19.	0.0	0
39	Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan. <i>BMC Infectious Diseases</i> , 2017, 17, 261.	2.9	2
40	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2017, 35, 88-99.	0.3	0

#	ARTICLE	IF	CITATIONS
41	Drugs for HIV Infection. , 2017, , 1293-1308.e2.		17
42	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y MicrobiologÍa ClÁnica, 2017, 35, 88-99.	0.5	12
43	Pharmacokinetic analysis of nevirapine extended release 400Âmg once daily vs nevirapine immediate release 200Âmg twice daily formulation in treatment-naïve patients with HIV-1 infection. HIV Clinical Trials, 2017, 18, 189-195.	2.0	3
44	Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 813-829.	3.3	57
45	Structureâ€based nonâ€nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants. Chemical Biology and Drug Design, 2021, 97, 4-17.	3.2	8
46	Deficient Reporting and Interpretation of Non-Inferiority Randomized Clinical Trials in HIV Patients: A Systematic Review. PLoS ONE, 2013, 8, e63272.	2.5	25
47	Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia. PLoS ONE, 2015, 10, e0128131.	2.5	4
48	Long-Acting, Injectable Antiretroviral Therapy for the Management of HIV Infection: An Update on a Potential Game-Changer. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	2